Rathnakar Bethi

Dr. Rathnakar Bethi

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NGNarayana Murthy Ganta
Narayana Murthy Ganta
GGGangaraju Gedda
Gangaraju Gedda
RBRathnakar Bethi
Rathnakar Bethi
MSMavurapu Satyanarayana
Mavurapu Satyanarayana
BYBhaskar Yamajala
Bhaskar Yamajala
TBTuniki Balaraju
Tuniki Balaraju

16 November 2020 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
RBRathnakar Bethi
Rathnakar Bethi
GKGajula S. Kumar
Gajula S. Kumar
SMSaleem P. Mahammad
Saleem P. Mahammad
SGSridhar Gattu
Sridhar Gattu
SKSambaru Kalyani
Sambaru Kalyani
MSMavurapu Satyanarayana
Mavurapu Satyanarayana

1 October 2021 in Letters in Organic Chemistry
Verified
Journal Article
Closed access
PDF file
GKGajula Shyam Kumar
Gajula Shyam Kumar
RBRathnakar Bethi
Rathnakar Bethi
SGSridhar Gattu
Sridhar Gattu
SJSurender Singh Jadav
Surender Singh Jadav
NRNimma Rameshwar
Nimma Rameshwar
MSMavurapu Satyanarayana
Mavurapu Satyanarayana
A series of 2-heteroaryl benzimidazole-chalcone hybrids were synthesized and the anticancer activity was estimated by MTT assay in human breast, lung, colon, and ovarian cancer cell lines. The biological results indicate that the compounds showed good anticancer activity with IC50 value in the range of 0.056-19.5 μM. Compound 11b with hexa methoxy groups, bearing three methoxy groups on each terminal aryl ring exhibited a significant IC50 value (56 nM) against human breast carcinoma cells, which is 37 times higher potency in comparison with the reference Etoposide. Further compounds substituted variably with methoxy and nitro groups on the phenyl ring of chalcone showed more promising anticancer activity than the compounds with unsubstituted phenyl ring or variably alkyl-substituted phenyl ring of chalcone. The molecular docking results indicate that the synthesized compounds bind in the active site of Abl tyrosine kinase, the target of anticancer drug Imatinib. The present study provides the synergistic effect of hybrids, benzimidazole-chalcones as potential anticancer agents that will aid in the discovery of new anticancer agents.

25 May 2021 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
RBRathnakar Bethi
Rathnakar Bethi
KSKislay Kumar Sinha
Kislay Kumar Sinha
SPSurendra Rajit Prasad
Surendra Rajit Prasad
MKMohd. Imran Khan
Mohd. Imran Khan
CNChelimela Narsaiah
Chelimela Narsaiah
MSMavurapu Satyanarayana
Mavurapu Satyanarayana